Biologics

Bioventus Launches GELSYN-3™ for Treatment of Knee Osteoarthritis Pain

DURHAM, N.C.–(BUSINESS WIRE)– August 9, 2016

Bioventus, a global leader in orthobiologic solutions, today announced it has launched GELSYN-3, a three-injection hyaluronic acid (HA) product for pain relief associated with osteoarthritis (OA) of the knee. A 3-injection regimen delivers long-lasting OA knee pain relief for up to six months.1

“GELSYN-3 expands the product offering for our US Active Healing Therapies business and gives patients and physicians another choice for effective knee OA pain management,” said Tony Bihl, CEO of Bioventus. “This launch is another milestone at Bioventus and we expect GELSYN-3 to help accelerate our growth as a leader in orthobiologics.”

OA of the knee involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Each injection of GELSYN-3 delivers a highly purified solution of hyaluronic acid and is clinically proven effective and safe.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical, to make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

1. Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial) vs. hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage. 2011: 19:1294-1300. This article references Sinovial, the former brand name of GELSYN-3.

GELSYN-3 Summary of Indications for use:

GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy and simple analgesics (e.g., acetaminophen).

Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into knees of patients having knee joint infections or skin diseases or infections in the area of the injection site. GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling at www.GELSYN3.com, or by calling customer service at 800-836-4080.

Bioventus and the Bioventus logo are registered trademarks and GELSYN-3 is a trademark of Bioventus LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005877/en/

 

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close